跳至主要内容
临床试验/NCT01896635
NCT01896635已完成2 期

Faecal Microbiota Transplantation for Chronic Active Ulcerative Colitis - A Randomised Double Blind Controlled Study of Efficacy & Safety

The University of New South Wales6 个研究点 分布在 1 个国家目标入组 81 人开始时间: 2013年11月最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
81
试验地点
6
主要终点
Composite Clinical remission & Endoscopic remission / response as measured by Mayo subscores

研究概览

简要总结

The purpose of this study is to determine whether fecal microbiota transplantation (FMT) is safe and efficacious in the treatment of chronic active ulcerative colitis (UC) by conducting a randomised controlled trial

详细描述

This study involves the assessment of the safety and efficacy of FMT in the treatment and induction of remission for patients with mild to moderate ulcerative colitis. It is a double blind study with patients randomised in a 1:1 manner to either active or placebo therapy

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Ulcerative colitis >3 months duration
  • Active mild-moderate ulcerative colitis (Mayo 4-10)
  • Ulcerative colitis of any extent except isolated proctitis < 5cm
  • Live within driving distance of clinical site (to attend multiple study visits)

排除标准

  • Pregnancy
  • Active gastrointestinal infection
  • Other gastrointestinal disease / comorbidities
  • Prior colonic surgery
  • Recent antibiotic or probiotic use
  • Prednisone > 20mg
  • Monoclonal antibody immunosuppressive therapy

结局指标

主要结局

Composite Clinical remission & Endoscopic remission / response as measured by Mayo subscores

时间窗: 8 weeks

次要结局

  • Clinical remission as measured by Mayo subscores(8 weeks)
  • Endoscopic healing as measured by UCEIS(8 weeks)
  • Treatment failure rate as defined by Mayo subscores(8 weeks)
  • Safety and tolerability as measured by adverse event data(8 weeks)
  • Clinical response as measured by Mayo subscores(8 weeks)
  • Quality of life as measured by IBDQ(8 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Dr. Sudarshan Paramsothy

Gastroenterologist / PhD candidate

The University of New South Wales

研究点 (6)

Loading locations...

相似试验